Marksans Pharma Secures USFDA Approval for Omeprazole Tablets

has received final USFDA approval for its 20mg Omeprazole delayed-release tablets through its US subsidiary, Marksans Pharma Inc. The product, an over-the-counter equivalent to AstraZeneca’s Prilosec 20mg, is used to treat heartburn, gastric and duodenal ulcers, erosive esophagitis, and GERD by reducing excess stomach acid. This approval under the ANDA pathway enables Marksans to enter the US market for acid reflux treatments with a cost-effective alternative, strengthening its gastrointestinal portfolio and supporting growth in its North American business. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.